NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering
Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its common stock at a price of $1.05 each, resulting in total gross proceeds of $8 million before deducting commissions and estimated offering expenses. The company plans to use the proceeds toward the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and…







